Health Care Biotech and Pharmaceuticals

More

  • 2015 has been a fantasic year: Actelion CEO Tuesday, 9 Feb 2016 | 1:28 AM ET
    2015 has been a fantasic year: Actelion CEO

    Jean-Paul Clozel, CEO of Actelion, says 2015 may be the company's best year, with sales crossing 2 billion Swiss francs thanks to the drug Opsumit.

  • Biotech stocks too risky? Friday, 5 Feb 2016 | 1:57 PM ET
    Biotech stocks too risky?

    RBC Capital Markets BioTech Analyst Michael Yee and CastleArk Management President & CIO Jerry Castellini discuss the bull and bear cases for biotech stocks.

  • Shkreli's attorney: He's been unfairly vilified Thursday, 4 Feb 2016 | 6:08 PM ET
    BRAFMAN FULL INTERVIEW

    Former Turing Pharmaceuticals CEO Martin Shkreli was scheduled to testify to Congress today, but exercised his 5th Amendment right to not incriminate himself. Shkreli's lawyer Benjamin Brafman, explains his client's position.

  • Martin Shkreli is helping people: Attorney Thursday, 4 Feb 2016 | 4:43 PM ET
    Martin Shkreli is helping people: Attorney

    Martin Shkreli's attorney Benjamin Brafman explains why he believes his client is doing more to help people in desperate need of certain drugs.

  • Shkreli didn't violate the law at Turing: Attorney Thursday, 4 Feb 2016 | 4:38 PM ET
    Shkreli didn't violate the law at Turing: Attorney

    Martin Shkreli's attorney Benjamin Brafman explains why he believes his client is being treated unfairly.

  • Shkreli attorney: Martin Shkreli is a 'genius' Thursday, 4 Feb 2016 | 4:29 PM ET
    Shkreli attorney: Martin Shkreli is a 'genius'

    Martin Shkreli's attorney Benjamin Brafman explains why he thinks his client is a hero and why Congress meant to embarrass his client.

  • Martin Shkreli takes on Congress Thursday, 4 Feb 2016 | 12:12 PM ET
    Martin Shkreli, former CEO of Turing Pharmaceuticals, prepares to testify before a House Oversight and Government Reform hearing on Capitol Hill, Feb. 4, 2016.

    Martin Shkreli, the former drug company CEO who's come under fire for massive drug price increases, refused to testify Thursday before a congressional committee investigating drug price hikes.

  • Duncan on Shkreli: Never seen such arrogance Thursday, 4 Feb 2016 | 10:37 AM ET
    Rep. Duncan on Shkreli: Never seen such arrogance

    Former Turing Pharmaceuticals CEO Martin Shkreli was escorted from a drug price hike hearing after pleading the Fifth Amendment. CNBC's Meg Tirrell reports on comments by Rep. John Duncan (R-Tenn.) on Shkreli's what he calls "arrogance."

  • Shkreli lawyer blames irreverence on youth Thursday, 4 Feb 2016 | 5:11 PM ET
    Martin Shkreli, former CEO of Turing Pharmaceuticals, prepares to testify before a House Oversight and Government Reform hearing on Capitol Hill, Feb. 4, 2016.

    "I intend to follow the advice of my counsel, and not yours," Martin Shkreli tells Rep. Trey Gowdy, smirking.

  • Martin Shkreli testifies on Capitol Hill Thursday, 4 Feb 2016 | 7:53 AM ET
    Martin Shkreli testifies on Capitol Hill

    Former Turing Pharmaceuticals executive Martin Shkreli will appear before Congress this morning, reports CNBC's Meg Tirrell.

  • Florida governor declares Zika emergency Wednesday, 3 Feb 2016 | 3:44 PM ET
    Aedes aegypti mosquitos known to carry the Zika virus.

    Florida Governor Rick Scott has declared a health emergency in four counties due to the Zika virus.

  • Shkreli attorney: I told him to stop talking Wednesday, 3 Feb 2016 | 3:35 PM ET
    Former drug executive Martin Shkreli (R) exits with his lawyer Benjamin Brafman at the U.S. Federal Courthouse in Brooklyn, New York February 3, 2016.

    After his hearing at Brooklyn court on Wednesday, Martin Shkreli will no longer be speaking to the press according to his new lawyer.

  • Merck revenue falls as dollar strengthens Wednesday, 3 Feb 2016 | 7:39 AM ET
    Merck KGaA is a German company in the chemical and pharmaceutical industry based in Darmstadt

    Merck reported a 2.5 percent fall in quarterly revenue, hurt by a strong dollar and declining sales of its Remicade arthritis treatment.

  • Drug store swept up in ‘sexist pricing’ storm Wednesday, 3 Feb 2016 | 7:10 AM ET
    Boots store

    U.K. drug store Boots has cut the prices on some of its products after it emerged it was charging women more than men for similar products.

  • Gilead shares pop 2% on earnings beat Tuesday, 2 Feb 2016 | 4:05 PM ET
    Gilead shares pop 2% on earnings beat

    Gilead Sciences Q4 EPS beat analysts' expectations, reports CNBC's Meg Tirrell.

  • Gilead beats on earnings, revenue Tuesday, 2 Feb 2016 | 4:00 PM ET
    A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, California.

    Gilead reported quarterly earnings and revenue on Tuesday that beat analysts' expectations, boosted by sales of its drugs in Japan.

  • Waksal’s Kadmon said to plan IPO, sans Waksal Tuesday, 2 Feb 2016 | 3:33 PM ET
    Samuel Waksal

    Kadmon, the biotechnology company founded by ImClone's Sam Waksal, is preparing to file confidentially for an initial public offering, sources say.

  • An overview on the biotech sector: Pro Tuesday, 2 Feb 2016 | 3:30 PM ET
    An overview on the biotech sector: Pro

    Sam Isaly, OrbiMed Advisors, discusses the biotech sector and how cases like the Zika virus impact the health sector.

  • Ex-drug CEO Shkreli hires Jay Z, Diddy lawyer Tuesday, 2 Feb 2016 | 1:11 PM ET
    Martin Shkreli during an earlier trip to U.S. Federal Court in Brooklyn, New York December 17, 2015.

    Former drug CEO Martin Shkreli, facing fraud charges, hired a new lawyer who has previously represented Jay Z and Michael Jackson.

  • No quick cure yet for Zika virus Monday, 1 Feb 2016 | 10:50 PM ET
    Impact of Zika Virus on Drugmakers

    A possible vaccine for the Zika virus is still three to 10 years away, says Max Macaluso, an analyst at The Motley Fool.

Contact Biotech and Pharma

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

 

  • Dan Mangan is a reporter covering health care for CNBC.com.

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.